Trials / Completed
CompletedNCT00045994
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SILVER Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (planned)
- Sponsor
- Synvista Therapeutics, Inc · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 (210 mg) or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALT-711 |
Timeline
- Start date
- 2001-08-01
- Primary completion
- 2002-01-01
- Completion
- 2003-06-01
- First posted
- 2002-09-19
- Last updated
- 2009-07-29
Source: ClinicalTrials.gov record NCT00045994. Inclusion in this directory is not an endorsement.